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Phosphodiesterases (PDEs), the only known enzymes to degrade 3’,5’-cyclic nucleotides, are being pursued as 
therapeutic targets for a number of diseases, including those affecting the nervous system, cardiovascular 
system, fertility, immunity, cancer, and metabolism. Although clinical development programmes have so far 
focused exclusively on catalytic inhibition, emerging evidence supports therapeutically targeting PDE function 
in additional ways, such as enhancement of catalytic activity and/or normalization of altered 
compartmentalization, as well as the potential use of PDEs as disease biomarkers. Importantly, a more refined 
appreciation of the intramolecular mechanisms regulating PDE function and trafficking is emerging, making 






Conventional 3’,5’-cyclic nucleotide phosphodiesterases (PDEs) are members of a highly conserved 
superfamily of enzymes that degrade the canonical cyclic nucleotides 3’,5’-cyclic adenosine monophosphate 
(cAMP) and 3’,5’-cyclic guanosine monophosphate (cGMP) (1-6), as well as the non-canonical cyclic 
nucleotides 3’,5’-cCMP, 3’,5’-cUMP, 3’,5’-cIMP and c-di-GMP (7-9) (Figure 1). As extensively reviewed 
elsewhere (1), there are 11 families of PDEs that are grouped based on the homology of their C-terminal 
catalytic domain, and each PDE family has multiple isoforms that differ in terms of the length and complexity 
of their N-terminal regulatory domains (Figure 2). PDEs do not simply control the total cellular content of 
cyclic nucleotides, but rather create individual pockets or nanodomains of cyclic nucleotide signaling. It is this 
subcellular compartmentalization of cyclic nucleotide signaling that enables a single cell to respond discretely 
to multiple extracellular and intracellular signals. Thus, PDEs regulate a myriad of physiological processes, 
and their dysfunction has been associated with a number of pathophysiological states including those affecting 
the nervous system, cardiovascular system, fertility, immunity, cancer, and metabolism (Box 1). Because the 
location of a PDE is just as important to its overall function as is its catalytic activity, how the location of a 
given PDE isoform can change based on tissue type, age, or disease status—possibly due to factors such as 
activation of receptors, alterations in calcium signaling, or elevations in cyclic nucleotides—is of paramount 
importance when considering the therapeutic potential of a given PDE isoform (10-19) (Table S1).  
Importantly, no two PDE isoforms share the exact same combination of substrate specificity, tissue 
expression profile and subcellular localization (Table S1). This is quite important because there are a number of 
diseases where compartment-specific defects in cyclic nucleotide signaling have been identified. For example, 
the function of soluble guanylyl cyclase, but not particulate guanylyl cyclase, is significantly impaired in 
brains of Alzheimer’s patients and in vitro models of Alzheimer’s disease pathology (20-22), which would be 
expected to decrease cytosolic pools of cGMP. In contrast, in colon cancer, membrane-bound guanylyl cyclase 
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appears to be dysregulated/suppressed (23) and membrane-enriched PDE10A appears to be overexpressed 
(24), both of which would decrease membrane-proximal pools of cGMP. That said, cytosolic pools of cGMP 
may also be decreased in colorectal cancer cells, as PDE5A is also overexpressed in these cells (24), and—at 
least in heart and brain—PDE5 regulates pools of cGMP that are downstream of soluble guanylyl cyclases (25, 
26). 
With regard to compartment-specific changes in cAMP signaling, studies examining brain tissue from 
patients with bipolar disorder show no change in membrane but increased signaling in the cytosol, which is 
normalized by the classic mood stabilizer lithium (27-32). Other disease states where compartment-specific 
defects in cyclic nucleotide signaling have been noted include—but are not limited to—erectile dysfunction 
(33), hypertension (34), cardiac hypertrophy (25, 35), acrodysostosis (36-39), and Huntington’s disease (40, 41). 
The unique substrate/localization profile offered by each PDE isoform offers multiple degrees of freedom in 
the context of therapeutic targeting. As such, isoform-specific targeting could enable selective restoration of 
cyclic nucleotide signaling in affected compartments (i.e., provide efficacy) without affecting cyclic nucleotide 
signaling elsewhere (i.e., avoid side effects).  
As reviewed in detail below, there has been and continues to be strong interest in developing PDE-
targeted therapeutics for a number of diseases. Unfortunately, the majority of PDE-targeted therapeutics on 
the market are simply competitive blockers of substrate binding at the catalytic site that lack the ability to 
selectively target a specific isozyme within a single PDE family or sub-family. That said, novel therapeutic 
strategies are currently being explored to increase the selectivity and specificity with which PDEs are targeted 
(e.g., by targeting protein-protein interactions). Further, PDE activators are now being considered as agents for 
treating select diseases, as are the exploitation of PDEs as biomarkers for diagnosis and/or patient selection 
(Box 2). Here, we review the clinical successes and failures of PDE inhibitors to date and describe a number of 




Successes and failures in the clinic.   
Several PDE family-selective inhibitors have successfully reached the market, targeting diseases such as 
psoriasis, COPD and erectile dysfunction. On the other hand, many potent and selective PDE inhibitors have 
also failed when tested in clinical trials. We will summarize the main achievements and pitfalls in the 
development of marketed PDE inhibitors to consider factors that currently limit the effectiveness of such 
therapeutic agents. 
 
Marketed PDE inhibitors (PDEi’s) 
The non-selective PDE1 inhibitor (PDE1i) vinpocetine is not FDA approved but is available in over-the-counter 
supplements (e.g., Cavinton or Intelectol, Richter Gedeon; Cognitex, Life Extension) claiming to improve 
memory and recovery from stroke, likely due to increasing vasodilation (42). As extensively reviewed 
elsewhere (42), a number of clinical trials have examined the cognition-enhancing effects of vinpocetine—
either alone or in combination with another compound (e.g., caffeine or Ginko Biloba)—and have generally 
found improvement in healthy volunteers, individuals with cerebral hypofusion, and possibly aged 
individuals, but no improvement in AD patients. Reports of side effects associated with vinpocetine have 
generally been minimal (Table 1, (43)).  
Several PDE3i’s are currently marketed, with Cilostazol and Milrinone perhaps the most widely 
known. Cilostazol was officially approved by the FDA in 1999 for intermittent claudication; however, its off-
label uses include secondary prevention of cerebrovascular accident, percutaneous coronary intervention and 
coronary stent stenosis (c.f., (44)). Although cilostazol improves function across a number of domains, it is also 
associated with serious side effects (Table 1). As such, cilostazol is contraindicated for patients with severe 
heart failure, hepatic impairment, or renal impairment (45). Milrinone increases contractility of the heart and is 
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FDA approved for short-term management of severe congestive heart failure. It is particularly used in the 
context of end-stage heart failure for patients who prove resistant to optimal therapy and for those awaiting 
cardiac transplant (46). That said, the clinical utility of milrinone has been limited by significant side effects 
(Table 1) and the fact that it is cleared through the kidneys (i.e., generally not used in patients with renal 
failure) (46).  
Three so-called “second-generation” PDE4i’s are currently FDA approved, with a 4th compound 
marketed as an over-the-counter supplement. Roflumilast is a PDE4i that is FDA approved as an add-on 
therapy for chronic obstructive pulmonary disorder (COPD; Table 1). It is considered a third line treatment 
due to its gastrointestinal and weight loss side effects; however, it is reported to improve sugar metabolism in 
obese patients and may decrease cardiovascular events in patients with COPD (47). Apremilast is FDA 
approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis (48-50) and is also 
being tested in a Phase IV trial for active ankylosing spondylitis (see below). The most common side effects for 
both of these orally-administered second-generation PDE4i’s are the same that plagued first-generation 
PDE4i’s (i.e, gastrointestinal disturbances; Table 1), albeit with much improved therapeutic windows (48). 
Crisaborole is a topically-applied ointment that is FDA approved for treatment of moderate atopic dermatitis 
in patients >2 years old. Given the topical nature of the drug, gastrointestinal side effects are avoided and, 
instead, hypersensitivity reactions are the major possible side effect. Clearly, there is an anti-inflammatory 
theme shared amongst these FDA-approved PDE4i’s. Zembrin in a non-selective PDE4 inhibitor (also acts as a 
5-HT uptake inhibitor) that is not FDA-approved but is a component of a number of herbal supplements 
claiming calming or mood-stabilizing properties (e.g., Calm, Doctor’s Best; Mood, Procera; Nutri-calm, 
Nature’s Sunshine) (51). fMRI imaging of the amygdala in humans supports an anxiolytic-like effect of 
Zembrin (51). Further, a Phase I trial found Zembrin was well tolerated and improved cognitive flexibility, 
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executive function, mood and sleep (52). As noted below, a number of PDE4i’s are currently being pursued to 
improve cognitive functioning (see below). 
There are 4 PDE5i’s currently FDA approved and marketed in the U.S., with a 2 additional PDE5i’s 
marketed outside the U.S.. All 6 PDE5i’s were originally marketed for erectile dysfunction (Table 1), with the 
most recent approval for avanafil based on its much more rapid onset of action. Sildenafil later received a 
secondary approval for pulmonary hypertension (contraindicated for pediatric patients, veno-occlusive 
disease, or sickle cell disease), as did tadalafil. These FDA-approved PDE5i’s are generally considered safe and 
well tolerated, with no increase in cardiac mortality or myocardial infarction (53). Given their shared 
mechanism of action, it is perhaps not surprising that they share largely similar side effect profiles (Table 1) 
with headache, flushing, dyspepsia, and vision disturbances being the most common adverse events (53). 
Interestingly, udenafil (Zydena, Mezzion Pharma)—one of the PDE5i’s used to treat erectile dysfunction in 
Korea, Russia and Philippines (54, 55)--has also been reported to improve cognitive function in patients with 
erectile dysfunction (56, 57). 
The success of a number of marketed PDEi’s validates PDEs as appropriate therapeutic targets in many 
pathological conditions. However, the presence of unwanted side effects resulting from the inability to target 
individual isoforms is the major limiting factor to success. It is notable that of the 11 PDE families, only agents 
that attenuate the activity of PDEs 1, 3, 4 and 5 have made it to market, despite significant efforts targeting the 
inhibition of other PDE families (see next). 
 
Failed PDEi clinical trials 
Despite the successes noted above, a number of PDEi’s that entered the clinic failed to make it to market. 
Pfizer’s selective PDE2i PF-05180999 was originally considered a candidate for cognitive impairments 
associated with schizophrenia based on its preclinical profile (58); however, it was brought into the clinic for 
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migraine. Despite the completion of earlier Phase 1 safety and tolerability studies, additional trials were 
terminated early due to safety concerns (Table 2). Exisulind inhibits both PDE2A and PDE5A (which are 
overexpressed in a number of precancerous and cancerous cell types) and triggers apoptosis in 
precancerous/cancerous cells with minimal effects on healthy cells (c.f., (59, 60)). Despite promising findings in 
multiple clinical trials, exisulind failed to secure FDA approval in 2000 due to deficiencies in safety and 
efficacy (Table 2, c.f., (59, 60)).   
As noted above, Cilastozol has gained FDA approval for intermittent claudication; however, clinical 
trials for other indications, such as type 2 diabetes mellitus peripheral neuropathy, have failed (61). That said, 
cilostazol significantly improved walking speed in these patients, suggesting improved peripheral blood flow 
as would be expected based on its current approved indication (61). 
The PDE4i cilomilast (Ariflo, GlaxoSmithKline) gained FDA approval in 2003 as a second-line 
treatment for COPD in patients who are poorly responsive to salbutamol (62). However, cilomilast never made 
it to market due to the severely dose-limiting nature of gastrointestinal side effects (e.g., nausea and vomiting, 
diarrhea, and abdominal pain (48)). The fact that cilomilast elicited more pronounced side effects relative to the 
other systemically-delivered PDE4i’s described above may be related to preferential inhibition of the PDE4D 
family relative to the other PDE4 subtypes (62). A novel PDE4i ASP9831 was tested in Phase I and II trials for 
non-alcoholic steatohepatitis based on preclinical findings, but failed to improve biochemical biomarkers of the 
disease (63). As target engagement in the organ of interest was not confirmed (63), the reasons underlying the 
lack of efficacy remain unclear.  
A number of clinical trials have attempted to extend therapeutic indications for PDE5i’s, but have 
failed. As reviewed extensively elsewhere (42), a number of trials have tested the effects of sildenafil or 
vardenafil on various measures of cognition in healthy volunteers or patients with schizophrenia and have 
largely found no effects (64-68). That said, one report from an Iranian clinical trial did report an improvement 
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in negative symptoms in patients with chronic schizophrenia when sildenafil was administered in addition to 
risperidone (69). Several studies were initiated to study sildenafil and/or tadalafil in patients with Duchenne or 
Becker Muscular dystrophy, with the hopes that the vasodilatory properties of the drugs would improve 
muscular ischemia; however, clinical trial outcomes have been mixed (Table 2; (70, 71)). 
Two PDE9i’s have been tested in the clinic for cognition-enhancing effects. Although PF-04447943 was 
found to be safe and well-tolerated, it failed to improve either cognition or dementia-related behavioral 
disturbances in a Phase II clinical trial (72). Similarly, BI 409306 was reported as safe and well tolerated in 
healthy subjects as well as patients with AD or schizophrenia; however, no positive effects on cognition were 
observed in either patient population (https://www.boehringer-ingelheim.com/PDE9-Inhibition-in-AD, 
accessed 04/30/19; (73-76)). Despite a failure to improve cognition in patients with schizophrenia, BI 409306 is 
still being tested in the clinic for prevention of schizophrenia relapse and prevention of first psychotic episode 
(Table 3). The failure of PDE9i’s to improve functioning in AD may be related to the fact that brain PDE9A is 
enriched in the nucleus and membrane (10) and, thus, is not in a position to directly regulate the cytosolic 
pools of cGMP that appear to be dysregulated in Alzheimer’s disease (20-22).  
A number of clinical trials have tested the PDE10i PF-02545920 in schizophrenia and Huntington’s 
disease (Table 2-3). Despite widely replicated efficacy in a number of preclinical assays intended to measure 
schizophrenia-relevant behaviors  (e.g., (77, 78)), PF-02545920 failed to improve symptoms in patients with 
either exacerbated, stable, or sub-optimally treated schizophrenia (Table 2; (79)). Further, in at least 1 trial, 
there were reports of motoric side effects such as dystonia (79).  Pfizer attempted to reposition PF-02545920 for 
Huntington’s disease based on decreased striatal expression of PDE10A being found in patients (Box 2) and 
promising efficacy of PDE10i’s in preclinical models of the disease (41, 80, 81). Unfortunately, PF-02545920 
failed to improve symptoms in patients with Huntington’s 
(https://clinicaltrials.gov/ct2/show/results/NCT02197130?sect=X70156#outcome1, accessed 04/30/19), and so 
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efforts for this disease indication were terminated (https://clinicaltrials.gov/ct2/show/NCT02342548, accessed 
04/30/19). Several other PDE10i’s have also been pursued in the clinic for schizophrenia and/or HD, with some 
efforts subsequently suspended or terminated (Table 2) and others ongoing (Table 3—see more below). 
The unsuccessful translation of these PDEi’s from promising preclinical data to human testing suggest 
that therapeutic approaches targeting PDEs need to extend beyond occlusion of the enzyme’s catalytic site. Of 
particular note are the numerous failures seen in nervous system disorders, even when target engagement was 
verified. Expression of PDEs in the brain is particularly complex, with PDE isoforms differentially expressed 
across circuits, cell-types, and subcellular domains (10, 43, 82, 83). Thus, the challenge in evaluating the clinical 
potential for the next generation of PDE-modulating drugs is to gain novel insights about disease-related 
changes in PDE structure, function and regulation to understand how PDEs should be targeted in a 
compartment-specific manner for therapeutic gain. 
 
PDE inhibitors in development. 
Given the clinical successes of PDEi’s noted above, it is not surprising that traditional PDEi’s are still very 
much being pursued as potential therapeutics, particularly in the context of the central nervous system (CNS), 
cardiovascular system, reproductive system, cancer and metabolic disorders (Table 3). These efforts include 
the development of new chemical entities as well as repurposing of existing entities. Thanks to advances in our 
understanding of structural differences that exist between PDEs, coupled with extensive years-long medicinal 
chemistry efforts to optimize structure-activity relationships, more recently developed PDEi’s have been vastly 
improved in terms of selectivity and potency and have even demonstrated novel modes of action in some 
cases (i.e., acting as a negative allosteric modulator instead of direct catalytic inhibitor; (84-87)). Despite these 
advances in new chemical entities, there is still significant efforts to repurpose older PDEi’s. Drug repurposing 
efforts can be driven by computational or experimental approaches; however, most drug repurposing efforts 
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have been driven either by a better understanding of pharmacology or by a retrospective analysis of clinical 
effects that were observed during trials or marketed use of a drug for its original indication (c.f., (88)). Indeed, 
the PDE5i sildenafil was originally brought into clinical trials for angina but—following observations made by 
clinicians in that trial—was later repurposed for erectile dysfunction. Drug repurposing has several 
advantages including reduced risk and substantially reduced timelines and cost (e.g., $300 million for 
repurposed drug versus $2-3 billion for new chemical entity) due to the fact that the drug would already have 
passed preclinical and Phase I safety testing and possibly even formulation development (88). That said, there 
are a number of barriers to recouping expenses incurred by drug repurposing trials, particularly when they are 
carried forward by an entity other than the patent holder or following the expiration of the original patent (see 
(88) for further discussion).  
 
Non-selective inhibitor 
The non-selective PDE3-4-10-11 inhibitor Ibudilast, which also inhibits glial cell activation, is approved for use 
in Japan as a bronchodialator and has long been of interest as a therapeutic approach for neuropathic pain and 
substance abuse/withdrawal (89, 90). Recent clinical trials have tested Ibudilast in the context of amyotrophic 
lateral sclerosis, pain,  as well as opiate, methamphetamine, and alcohol abuse (Table 3) and positive effects 
have been reported for all trials completed to date (91-94).  
 
PDE1 inhibitors 
The broad PDE1 inhibitor ITI-214, which shows picomolar IC50s for PDE1A, PDE1B and PDE1C in enzymatic 
assays and >1000-fold selectivity versus its nearest neighbor PDE4 (95, 96), is being explored for CNS and non-
CNS indications. ITI-214 demonstrates cognition-enhancing effects in rodent models of long-term memory and 
working memory deficits (95-97), mimicking effects of a dopamine receptor 1 (D1) agonist (97) and occurring 
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at doses that leave efficacy of the antipsychotic risperidone intact (95).  Although the target mediating the 
cognition-enhancing effects of ITI-214 remains undetermined, PDE1B may be the most likely candidate given 
its expression in D1-expressing neurons (97) along with the fact that the a PDE1B-selective inhibitor showed 
similar cognition-enhancing effects (98). ITI-214 was moved into the clinic, with potential applications for 
cognitive deficits associated with schizophrenia, AD, and Parkinson’s Disease (96), with safety and tolerability 
established in healthy volunteers and patients with schizophrenia (Table 3). ITI-214 is also being explored in 
the clinic for heart failure (NCT03387215) given its ability to improve cardiac function in dog and rabbit 
models of heart failure (99) as a consequence of its inhibition of PDE1C (99). 
 
PDE2 inhibitors  
Like the PDE1i described above, a number of highly selective PDE2i’s have demonstrated cognition-
enhancing, anxiolytic and anti-depressant like-effects in animal models (c.f., (100)). TAK-915 entered Phase I 
trials to correlate plasma exposures with central target engagement with the purpose of informing dose 
selection for future trials targeting cognitive impairment in schizophrenia (101-103) (Table 3). Looking beyond 
the brain, PDE2i’s may hold relevance for cardiovascular function since elevated PDE2A expression has been 
found in failing human hearts as well as a large number of animal models of heart disease (c.f., (104)). Further, 
PDE2i’s may hold promise as an antifungal treatment for moderate to severe candidiasis infections, given that 
genetic deletion of pde2a reduces virulence and biofilm integrity of the fungal pathogen (c.f., (105)). 
   
PDE3 inhibitors 
Despite its existing FDA approval, the efficacy and safety of cilostazol is still very much a topic of 
investigation, with 27 active clinical trials registered on clinicaltrials.gov (accessed 04/30/2019) and 54 more 
drawn to a close within just the past 10 years. Numerous recent Phase IV studies appear focused on 
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broadening the therapeutic indications of cilostazol to include vasculature-related insults and nephropathies 
associated with Type 2 diabetes (Table 3), and recent reports suggest largely positive effects (44, 61, 106, 107). 
One study explored the efficacy of cilostazol in chronic tinnitus, and reported some improvement (108). 
Several prospective and retrospective studies have examined cilostazol as a primary or adjunctive treatment 
for cognitive deficits associated with AD and schizophrenia; the majority of which demonstrated positive 
effects of cilostazol on cognition (see (42) for review). The mechanism by which cilostazol elicits improved 
cognition has yet to be determined empirically. Given there is very little expression of PDE3A or PDE3B in the 
brain (83, 109), it may be likely that cognition-enhancing effects of cilostazol are driven by increased cerebral 
blood flow that comes with chronic—but not acute—dosing as opposed to inhibition of PDE3 isoforms directly 
in the brain (e.g., (110)).  
Novel therapeutic applications of cilostazol are also being explored in preclinical studies. For example, 
oral cilostazol (30 mg/kg) improved retinal stress, ischemia, and ganglion cell death in a rat model of diabetic 
retinopathy (111). In addition, PDE3A knockout (KO) mice are infertile (112) and chronic administration of 
cilostazol blocks pregnancy in naturally-cycling swine (113), suggesting potential utility of PDE3i’s for birth 
control or regulating in vivo oocyte maturation in the context of assisted reproduction. Indeed, administration 
of cilostazol to superovulated mice was able to improve in vitro fertilization rates of subsequently harvested 
oocytes, possibly by virtue of synchronizing the oocyte maturation (114). Because of the promise of PDE3 as a 
therapeutic target, coupled with concerns over side effect associated with cilostazol, alternative PDE3 
inhibitors are currently being sought in hopes of retaining efficacy associated with this target while avoiding 





The PDE4 family is arguably the most studied of all the PDE families. A number of clinical trials have tested 
the effect of apremilast for indications beyond psoriasis and arthritis. Two Phase II studies are testing the 
efficacy of apremilast in combination with phototherapy to produce repigmentation in patients with Vitiligo 
(Table 3). Interestingly, a recent case report showed apremilast dramatically improved repigmentation in a 
woman with treatment-resistant Vitiligo (118). Multiple case reports have also described an ability of 
apremilast to improve symptoms in patients with treatment-resistant erosive oral lichen planus (119-121), 
perhaps motivating the recently registered Phase II study that will test the ability of apremilast to improve 
genital erosive lichen planus (Table 3).   
Additional indications are also being explored for roflumilast. Phase IV studies showed roflumilast 
reduced fat mass and, thus, body weight in obese women with polycystic ovary syndrome (PCOS); however, 
these reductions were smaller than those elicited by liraglutide (Table 3; (122, 123)). The PDE4 inhibitor TAK-
648 is being tested in the clinic in patients with Type 2 diabetes, based on preclinical data supporting such an 
indication (124). Roflumilast has also been tested for its ability to improve cognition and information 
processing in healthy humans, with promising results observed at a dose previously indicated as being devoid 
of side effects (125). Patients with stabilized schizophrenia receiving adjuvant roflumilast in a small Phase II 
trial showed no improvement in working memory but did show some improvement in verbal learning and 
memory (126).  Given these positive findings, roflumilast was tested in elderly subjects who demonstrated no 
change in spatial memory but improved verbal word memory with roflumilast treatment (127). Numerous 
preclinical studies have long pointed to the therapeutic potential of PDE4i’s in the context of schizophrenia 
and cognition (128-131). 
Cognition-enhancing effects have also been reported for the PDE4i HT-0712, which improved long-
term memory for word-lists without serious adverse events in elderly subjects experiencing cognitive decline 
(http://www.dartneuroscience.com/press_release/july_22_2008.pdf). The cognition-enhancing effect of HT-
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0712 in humans is consistent with previous reports in mice (132, 133). The PDE4D negative allosteric 
modulator BPN14770 is also being pursued for improving cognitive impairment and has been tested for safety 
and/or efficacy in healthy elderly subjects, healthy volunteers with scopolamine-induced cognitive 
impairment, and adult males with Fragile X Syndrome (Table 3). In a press release, BPN14770 was described as 
having good safety and oral bioavailability and an ability to improve working memory in healthy elderly 
adults (http://tetradiscovery.com/wp-content/uploads/2016/11/FINAL-Tetra-Phase-1-121616-FINAL.pdf; 
accessed 04/30/19). These effects in humans are consistent with preclinical studies showing BPN14770 
improved a number of behaviors in a mouse model of Fragile-X Syndrome and antagonized the amnestic 
effects of scopolamine in mice (134, 135). Based on preclinical studies showing anxiolytic and cognition-
enhancing effects (136), the PDE4i GSK356278 entered Phase I safety trials for Huntington’s disease but 
adverse events limited the highest dose to that achieving only ~50% occupancy in brain (Table 3; (136)). Other 
nervous system disorders for which preclinical evidence suggests a therapeutic potential of PDE4i’s include 
ischemic stroke (132, 137-140), traumatic brain injury (141), axon regeneration (142), and substance abuse 
disorders (both causes and consequences, (143-146)). 
McCune-Albright Syndrome is a disease affecting endocrine tissues, skin and bones and is caused by a 
mutation that results in constitutive activation of the G-protein alpha subunit Gαs (Gαs*). Preclinical studies 
show that while Gαs* triggers increased cAMP levels in some tissues, it actually results in decreased cAMP 
levels in other tissues due to a PKA-dependent upregulation of PDE activity, particularly that of PDE1 and 
PDE4 (129, 147, 148). Consistent with this upregulation of PDE4 activity, the PDE4i rolipram was able to 
reverse deficits in a Gαs mouse models (129, 130). A clinical trial is currently underway that is using PET 
imaging to measure PDE4 expression in the brain and peripheral organs of patients with McCune-Albright 
Syndrome (Table 3). 
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More recent work is examining PDE4 in the context of cancer. Both preclinical and clinical data suggest 
roflumilast may exhibit anti-tumor activity for B-cell lymphomas (149). The PDE4i rolipram, in combination 
with cAMP-elevating agents, has been shown to suppress triple negative breast cancer both in vitro and in vivo 
in mice (150). Apremilast similarly induced tumor regression in mouse models of colorectal cancer (151). 
Perhaps even more interesting, inhibition of PDE4D specifically, either with genetic tools or the PDE4Di Gebr-
7b, resensitized chemotherapy-resistant ER-positive breast cancer cells (152). Although PDE4i’s have yet to be 
extensively explored in cancer patients, these early studies provide promise for the chemotherapeutic potential 
of PDE4is.  
 
PDE5 inhibitors 
A number of recent clinical trials have explored additional disease indications that might benefit from the 
vasodilatory properties of PDE5i’s. A cream version of sildenafil has recently been tested in a Phase II study 
examining female sexual arousal disorder (Table 3) as well as a study in which improved blood flow in 
patients with secondary Raynaud phenomenon was observed (153). International consortiums are testing 
sildenafil in intrauterine growth restriction in hopes that the vasodilatory properties of the drug will improve 
uteroplacental perfusion and, thus, fetal growth (154, 155). Initial results suggest sildenafil improves fetal 
growth and maternal blood pressure across species, including human, sheep, rabbit, and rodents (156, 157). 
Several studies have also explored the effects of sildenafil, tadalafil, or vardenafil in the context of metabolic 
disorders such as Type 2 diabetes and obesity, with the hopes that the vasodilatory properties of these drugs 
would improve glucose tolerance and insulin signaling and, thus, improve other endpoints such as elevated 
body weight, nephropathy, and cardiomyopathy (Table 3). Tadalafil improved insulin secretion, endothelial 
function, and abdominal lean mass content in non-obese men (158), and chronic sildenafil improved 
glycometabolic control, ameliorated visceral adiposity, and prevented remodeling in diabetic cardiomyopathy 
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(159-162). That said, vardenafil failed to reduce cardiovascular risk in men with type 2 diabetes (163).  
Interestingly, the positive effects of sildenafil on adiposity and diabetic cardiomyopathy are suggested to be 
independent of sildenafil’s vasodilatory properties, rather being mediated by epigenetic signaling and/or a 
reduction of inflammatory chemokines (159-162). It is important to note, however, that one of the studies 
examining the effect of sildenafil on glucose homeostasis was terminated early due to safety concerns (Table 
2). With regard to other indications related to nephropathy and cardiomyopathy, sildenafil has also been 
tested against media-induced nephropathy, and tadalafil is being explored in the context of kidney stones and 
endocrine cardiomyopathy (Table 3). A meta-analysis of older clinical studies suggest PDE5i’s could be an 
effective medical expulsive therapy for distal ureteral calculi, albeit not significantly improved relative to 
tamsulosin (164). With regard to the brain, two early-stage clinical trials are testing the ability of sildenafil to 
reverse concussion-related reductions in cerebrovascular reactivity (Table 3).  
As described for PDE4i’s, a number of trials are exploring the therapeutic potential of PDE5i’s as 
chemopreventives for solid tumors, multiple myeloma, and head and neck squamous cell carcinoma. Early 
reports suggest combining sildenafil with the chemotherapeutic regorafenib is safe in patients with solid 
tumors (165). Further, a number of in vitro and animal models of colorectal cancer suggest that PDE5i’s, either 
alone or as part of a multi-chemotherapeutic regimen, demonstrate an ability to prevent tumor growth (e.g., 
(24, 165, 166)). Similarly, reports from both retrospective and prospective trials suggest tadalafil promotes 
tumor immunity in patients with head and neck squamous cell carcinoma (Table 3, (167, 168)). Although 
PDE5i’s show significant anti-tumor effects, particularly with regard to colorectal cancer, they do not produce 
complete anti-tumorigenic effects (23). This lack of complete efficacy may be related to the fact that membrane 
GCs are inhibited in colorectal cancer (23), but PDE5 may be primarily regulating cytosolic GCs (25, 26). 
Alternatively, it may be related to the fact that both PDE5 and PDE10A—the latter a membrane-enriched PDE 
(82, 169)—are overexpressed in colorectal cancer cells (24). Indeed, PDE10i’s also inhibit growth of colorectal 
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cancer cells (170, 171); however, when both PDE5 and PDE10 are inhibited, anti-tumor efficacy is improved in 
preclinical models (24). Although enthusiasm for PDE5i’s as chemopreventives is growing (172), it should be 
noted that PDE5i’s similarly prevented prostate carcinogenesis in preclinical models but did not appear to 
reduce risk or recurrence in clinical studies (173). Perhaps even more concerning, PDE5A appears to suppress 
melanoma cell invasion in mice (174) yet a recent systematic review and meta-analysis showed that PDE5i’s 
actually increase risk for melanoma and basal cell carcinoma in humans (175). 
 
PDE9 inhibitors 
Although PDE9i’s thus far have failed in the clinic for brain diseases, they may hold therapeutic potential for 
cardiovascular diseases. In a mouse model of sickle cell disease, the PDE9i BAY73-6691 had immediate benefits 
on acute vaso-occlusive events (176), and a Phase 1 clinical trial has recently completed looking at safety, 
tolerability and PK/PD of the PDE9i PF-04447943 in patients with sickle cell anemia (Table 3). PDE9i’s may also 
hold therapeutic potential for cardiovascular indications as PDE9A expression is upregulated by cardiac 
hypertrophy and cardiac failure. Indeed, the PDE9i PF-04449613 reverses heart disease in animal models by 
controlling pools of cGMP downstream of pGCs (25). 
 
PDE10i inhibitors 
Despite the PDE10i clinical failures described above, TAK-063 was tested in healthy controls and patients with 
schizophrenia. In healthy controls, TAK-063 was reported to be safe and well tolerated (177), altering the 
effects of ketamine on brain activity in healthy controls, particularly in the striatum, substantia nigra, and 
ventrolateral prefrontal cortex ( 
https://clinicaltrials.gov/ct2/show/results/NCT01892189?sect=X70156#outcome1,  accessed 04/30/19). In patients 
with schizophrenia, although TAK-063 failed to demonstrate a significant effect on the total PANSS score, 
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there was a trend that mirrored effects sizes normally seen with risperidone (178). Furthermore, TAK-063 did 
significantly improve a number of secondary endpoints relative to placebo (178). It is not entirely clear why 
TAK-063 was able to succeed where PF-2545920 failed. While one study suggested that TAK-063 activates the 
striatal direct and indirect pathways in a balanced manner and PF-254920 activates the direct pathway more so 
than TAK-063 (179), other studies have reported that PF-254920 activates these pathways equally (77, 180). It is 
notable that TAK-063—but not PF-254920—increased sensorimotor gating in rodents as measured by prepulse 
inhibition of acoustic startle (PPI) (179), suggesting PPI may more accurately predict antipsychotic-like effects 
of novel compounds. Preclinical studies are also exploring the therapeutic potential of PDE10i’s in the context 
of L-DOPA-induced dyskinesias (181) and alcohol abuse disorders (144). 
 
Inhibition of PDE7, PDE8 or PDE11 
Studies describing the physiological function of the PDE7, PDE8, and PDE11 families are now emerging; 
however, inhibitors have not yet reached the clinic. Like many of the PDE families discussed above, early 
research suggests that PDE7i’s and PDE8i’s may have positive effects in diseases where cognition, 
neuroprotection, neuroinflammation, and/or motor function are impaired (e.g., multiple sclerosis and/or 
Parkinson’s disease; (182-186)). Similarly, PDE11i’s may hold potential for treating age-related cognitive 
decline (83) or as an adjunctive treatment to improve lithium responsiveness in patients with bipolar disorder 
(187, 188). PDE7i’s may also hold promise in treating leukemia (189, 190), and PDE8i’s may have potential for 
treating disorders associated with reduced androgen production in males as PDE8i’s, particularly when 
applied in combination with PDE4i’s, stimulate Leydig cell steroidogenesis (191, 192).  
 




Although efforts to pharmacologically modulate PDE activity to date have largely focused on inhibition, there 
are several disease states where PDE activation may be warranted. Tissue-, brain region-, and subcellular 
domain-specific decreases in PDE expression/activity and/or increases in cyclic nucleotide signaling have been 
implicated in select disease states, including some age-related deficits (193-195), Huntington’s disease (196), 
social isolation (197), migrane (198-202), retinitis pigmentosa (203), infertility (112), prostate cancer (204), 
melanoma and basal cell carcinoma (175), cardiac hypertrophy (35, 205), acrodysostosis (36), and polycystic 
kidney disease (206). Indeed, Mironid have developed PDE4 longform specific activators (mechanism as yet 
unknown; Table 4) for the treatment of polycystic kidney disease where increased adenylate cyclase activity 
caused by overexpression of vasopressin  V2R receptors results in elevated cAMP levels that drive cyst growth 
and disease progression (207).  There are several natural mechanisms by which PDE activity can be activated 
(Figure 3), and it is our contention that these avenues could be manipulated phamacologically to trigger PDE 
activation. 
 One route to PDE activation is by way of tandem GAF (cGMP-specific and stimulated PDE, Anabaena 
adenylyl cyclases, and E. Coli FhlA) domains (208) (Figure 3B). Although GAF domains have been identified 
in over 7400 proteins, in mammals they are only are found in the PDE families 2, 5, 6, 10 and 11 (6, 209). For a 
vast majority of non-PDE GAF domains the activating ligand is unknown, however for PDEs we know that 
cyclic nucleotides bind to  these pockets (Figure 3). PDE2 and PDE5 are activated when cGMP binds the GAF 
domain (210-212), and PDE10 is activated by cAMP binding the GAF domain (213). In the context of activation, 
binding of cyclic nucleotides to GAF domains is thought to cause structural changes that relieve autoinhibition 
of the PDEs (Figure 3). In contrast, cGMP binding the GAF-A domain of PDE6 enhances protein-protein 
interactions that inhibit PDE6 catalytic activity (214). This suggests that blocking cGMP binding of the PDE6 
GAF domain may provide a means of promoting PDE6 activity. It also suggests it may be possible to both 
activate and inhibit GAF-containing PDEs with small molecules at a site distinct from the catalytic domain. 
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Indeed, PDE11A is activated when a cGMP analog—but not cGMP itself—binds the GAF domain (213). 
Further, even though cGMP binding of the GAF domain activates PDE5 (210), a number of other types of 
molecules that bind the GAF domain inhibit PDE5 in its activated—but not basal—state (215). This is 
consistent with the fact that GAF domains are known to bind a diverse array of small molecules that are 
unrelated to cyclic nucleotides (208). The fact that GAF domains are only found in PDEs in mammals (6) 
makes GAF domains of high interest in the context of drug targeting (216). Importantly, mammalian GAF 
domains are sufficiently structurally divergent from one another (e.g., low degree of homology between PDE 
families and the tandem GAF domians are preceded by variable N-terminal stretches) as to allow selective 
pharmacological targeting of individual PDE families (210). Together, this suggests the GAF domains may 
provide an inroad for targeting reagents that selectively activate a given PDE isoform while avoiding off-target 
activity. 
PKA or PKG phosphorylation of PDE3 (217, 218), PDE4 (217, 219), PDE5 (220), and PDE8 (221) is also 
known to activate catalytic activity in a negative feedback loop. In the case of PDE4, for example, catalytic 
activity is inhibited when the UCR2 regulatory domain “trans-caps” the catalytic site; thus, occluding cAMP 
from reaching the enzymatic core of PDE4  (85, 222) (Figure 3C). PKA phosphorylation of the UCR1 regulatory 
domain blocks the ability of UCR2 to trans-cap the catalytic site, which locks PDE4 in the active state (85). 
Notably, select PDE4Di’s allosterically inhibit catalytic activity by promoting “trans-capping” (141); whereas, 
phosphatidic acid activates PDE activity by inhibiting trans-capping in a similar but mutually exclusive 
manner to PKA (223-225). Furthermore, the dominant negative peptide “UCR1C”, which corresponds to UCR1 
sequence, also activates PDE4 activity by inhibiting trans-capping (226). These results provide proof of 
principle that activation of PDE4 may be achieved by either small molecules or biologics that prevent UCR2 
from adopting a trans-capping conformation. 
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 PDEs may also be activated by manipulating protein-protein binding interactions. PDE6 is unique in 
the fact that the heterodimeric holo-enzyme includes two inhibitory subunits that span the catalytic pockets of 
the dimer, thus occluding cGMP from the catalytic site (227) (Figure 3D). Binding of the GTP-bound α-subunit 
of the heterotrimeric G-protein transducin relieves PDE6 inhibition by binding to the C-terminal region of 
PDE6 and its inhibitory subunits (228). The full crystal structure of PDE6 is not yet available (229); however, 
recent cryo-EM work (230) has confirmed the predicted structural organisation of the holo-enzyme, albeit 
without sufficient detail to inform pharmacological targeting. The success in upregulating PDE6 activity via 
gene transfer to combat retinitis pigmentosa (203) (see following section) suggests that PDE6 activation could  
be a viable therapeutic strategy for the treatment of vision loss. As discussed in greater detail below, it may 
also be possible to increase PDE activity by preventing the binding of PDEs to binding partners that sequester 
or suppress activity. 
 
Gene therapy 
Viral transfer of PDE genes, agents that silence PDE gene expression (e.g. antisense, silencing or microRNAs) 
(174, 231-235), or gene editing (e.g., Crispr/Cas9) (236) might also prove a useful means of therapeutically 
targeting individual PDE isoforms (Figure 4).  The best characterized PDE gene therapy approach to date 
targets PDE6 activity in the retina. A loss of transducin-mediated activation of PDE6 results in elevated cGMP 
levels, which causes the loss of primary rods and, ultimately, vision (237). Expression of recombinant PDE6α 
in the retina via an adeno-associated virus (AAV-PDE6α) preserved retinal structure, photo-transduction, and 
vision in retinal degeneration (rd) mice, as did AAV-PDE6β (238, 239). AAV-PDE6α similarly rescued retinal 
deficits in a mouse model that mimics human retinitis pigmentosa mutations (240). Experiments injecting 
AAV-PDE6γ into the retina have also proven successful in mice (241). In dogs, delivery of recombinant PDE6α 
using a tyrosine capsid-mutant AAV8 was able to stabilize cGMP levels and improve survival of 
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photoreceptor rods and cones in PDE6α-mutant dogs; however, several adverse effects related to the AAV 
injection were identified (203). The recent development of synthetic AAV vectors that target the retina in non-
human primates may provide the answer to these problems in the future (242). Notably, two clinical trials are 
underway testing the safety and efficacy of PDE6 gene therapy in retinitis pigmentosa (PhI NCT02759952, PhII 
NCT03328130; clinicaltrials.gov accessed 12/04/18). 
 A rapidly evolving approach within the gene therapy field is optogenetic medicine, which combines 
viral delivery of recombinant, light-activated proteins with biomedical devices that emit light of the specific 
intensity and wavelength needed to activate those proteins (243). With the field of personalized bioelectronic 
implants quickly evolving, optogenetic-based biomedical approaches are being pursued for neurological 
diseases, cancer, cardiovascular disease and metabolic disorders (243). Given that optogenetic-based 
approaches have now entered clinical trials (243), it is worth noting here that light-activated PDEs have been 
identified in lower organisms (244-246) and engineered in the lab (247). Both are being explored as biological 
tools in higher organisms. Activating or inhibiting a given PDE by a spatially and temporally restricted light 
emission, as opposed to a systemically administered pharmacological agent, may prove an ideal approach for 
treating diseases where cyclic nucleotide signaling is down regulated in one tissue yet upregulated in another 
(e.g., aging; c.f., (248)). It might also provide a means of avoiding side-effects associated with targeting PDE 
activity in a specific tissue (e.g., nausea/emesis associated with inhibiting PDE4 in the area postrema).   
 
Targeting location 
As production of cAMP is utilized by a variety of different Gs-coupled receptors to transduce signals, 
compartmentalization of signaling intermediates is crucial to define physiological outcomes specific to each 
receptor (249). This compartmentalization of cyclic nucleotide signaling is achieved by virtue of PDEs being 
tethered to a precise cellular location via binding partners (Table S1). Thus, promoting or disrupting isoform-
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specific protein-protein interactions may prove a viable approach to therapeutically target PDEs in an isoform-
specific manner, a level of specificity that has not been achieved with pharmacological inhibitors to date 
(Figure 4).  
 Proof of principle for such an approach first emerged with studies using dominant negative (DN) 
PDEs, catalytically inactive mutants that would displace their endogenous PDE. Using specific DN-PDE4 
isoforms, in vitro studies have successfully altered perinuclear cAMP signaling (250),  β-arrestin-dependent 
desensitization of the beta2-adrenergic receptor (251, 252), growth control of prostate cancer cells (204), 
prostanoid receptor-mediated cAMP signaling (253),  glucagon-like peptide-1 release (254), and cAMP 
gradients at the centrosome (255). DN-PDE4 tools have also yielded beneficial effects in vivo. For example, viral 
delivery of a DN-PDE4A5 to the mouse hippocampus was able to rescue localized cAMP signaling deficits and 
hippocampus-dependent memory impairments that were caused by sleep deprivation (256-258). In contrast, 
overexpression of a DN-PDE4B1 in the forebrain of mice did not affect hippocampus-dependent memory, 
although it did enhance hippocampal long-term potentiation in male mice (259). This finding underscores the 
importance of understanding the role of specific PDE isoforms, because a homozygous mutation in PDE4B 
(Y358C) that greatly reduces activity of all PDE4B isoforms by virtue of attenuating interactions with the 
scaffold protein Disrupted In Schizophrenia 1 (DISC1) improves both long-term potentiation and memory as 
well as other mood-related behaviors (260). It is interesting to note that nature has developed its own 
dominant-negative approach with PDE4A7, a PDE isoform that is targeted to specific subcellular 
compartments but is catalytically dead (261).  
One point to consider in adopting a DN approach is the fact that a single PDE isoform can 
contribute to more than one function in a cell via its participation in multiple distinct signaling 
complexes, which involve mutually exclusive protein-protein interactions (262) (Table S1; Figure 4). 
For instance, PDE4D5 is involved in a number of processes common in almost all cells, such as cell 
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growth, cell orientation, desensitization of Gs-coupled receptors, and inactivating the 
phosphorylation of ubiquitous chaperone HSP20 (263). The ability for PDE4D5 to have all these 
functions in a cell is a result of it being localized in different compartments by different anchors (e.g., 
RACK1 at leading edge of cells, beta-arrestin at transmembrane receptors, and HSP20 in the cytosol; 
Figure4; (263)). It is clear that this is also the case for a number of other isoforms based on proven 
protein-protein binding interactions (e.g., in heart tissue/cells, PDE4D3 can bind to either the 
ryanodine receptor, HSP20, or an AKAP9/Potassium channel complex—see Table S1) or based on 
inference from the fact that the exact same isoform can be found localized to multiple subcellular 
domains (e.g., ~50% of PDE11A4 in neurons localizes to the cytosol while 25% is localized to the 
nuclear fraction and another 25% to the membrane compartment (82)). Thus, a non-selective DN 
approach has the potential to influence multiple domains within the cell. To achieve a compartment-specific 
manipulation of a given PDE isoform, one could mutate the binding site(s) that mediates a particular protein-
protein interaction. Mutating isoform-specific binding sites has also proven a useful approach, revealing an 
integrin α5-PDE4A5 complex regulates endothelial inflammation (264), a PDE3A1-SERCA complex regulates 
myocardium contractility (265), and DISC1-mediated sequestering of PDE4B regulates hippocampal function 
(260). An alternative approach is to develop a peptide or small molecule that specifically competes for a given 
protein-protein binding site (266). This approach would displace only a specific “pool” of a given PDE isoform, 
while leaving the vast remainder unfettered in their respective signaling complexes (Figure 4).  
Indeed, a recent review suggests cell-permeable, peptide disruptors effectively manipulate specific 
PDE isoforms in a compartment-specific manner (266) and evidence continues to build. More recently, a 
PDE4D-FAK disrupting peptide prevented direction sensing and invasion of melanoma cells (267, 268) and a 
PDE8A-Raf1 disruptor retarded cancer cell growth promoted by a Ras mutation (221). Interestingly, the same 
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PDE8A-Raf1 peptide has also been used to target T cell adhesion and migration and was more potent than a 
PDE8-specific inhibitor in reducing inflammatory signaling (267). The effectiveness of PDE displacement has 
also been demonstrated in vivo, where intraperitoneal injections of a PDE4-HSP20 disruptor significantly 
attenuated hypertrophy-induced cardiac remodeling (269). Disrupting PDE homodimerization (that is, a PDE 
monomer binding to itself) may also prove an effective way to target PDE function in a domain-specific 
manner. Disrupting PDE11A4 homodimerization using a peptide recognizing its GAF-B domain was shown to 
selectively remove PDE11A4 from membrane-bound complexes but not the cytosol, which may hold utility for 
improving responsivity to the mood stabilizer lithium (187) or age-related cognitive decline (83). Conversely, a 
peptide or mutation that could stabilize PDE11A4 homodimerization might prove useful in treating the 
deleterious psychological effects of social isolation (197). Targeting homodimerization of PDE2, PDE4, or PDE5 
may also relocate the enzymes by virtue of changing susceptibility to regulatory post-translational 
modifications (6, 270). Indeed, nature appears to have taken advantage of dimerization as a mechanism to 
regulate PDE trafficking. For example, when PDE10A2 heterodimerizes with PDE10A19, PDE10A2 is 
prevented from trafficking to the membrane as it normally does under conditions of homodimerization (271). 
Such complex-specific targeting of PDE function may be required to achieve efficacy in absence of unwanted 
side effects, particularly in cases where multiple subfamily isoforms orchestrate a variety of physiologic 
responses by virtue of different protein-protein interactions (e.g., targeting various PDE3 isoforms for 
cardiovascular disease (272)).  
 
Targeting post-translational modifications 
As post-translational modifications (PTM) directly regulate PDE activity and location, PTMs could be 
considered a point of therapeutic control (Figure 5). As described above, PKA or PKG phosphorylation of 
PDE3 (217, 218), PDE4 (217, 219), PDE5 (220), and PDE8 (221) will stimulate catalytic activity. Phosphorylation 
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can also influence PDE cellular location by virtue of preventing other PTMs that promote membrane 
association (e.g., Palmitoylation) or changing protein-protein binding interactions. A great example to 
illustrate these principals is PDE10A2. PDE10A2 is palmitoylated in its N-terminal region, which directs 
membrane targeting and trafficking to dendrites (169). If, however, PDE10A2 undergoes isoform-specific 
phosphorylation by PKA on Thr16 (273), palmitoylation of PDE10A2 is attenuated and the specific membrane 
localization is lost (169). Interestingly, phosphorylation on the same site also interferes with the scaffolding of 
PDE10A2 by AKAP150 (274). Hence, although PDE10A catalytic activity is not directly affected by this PTM, 
cyclic nucleotide levels should increase within this compartment due to the absence of PDE10. Preliminary 
evidence also suggests that PDE11A4 can similarly be shuttled between membrane and cytosolic 
compartments by virtue of phosphorylation of N-terminal serines, although this is likely by virtue of altering 
protein-protein interactions as opposed to a direct insertion into the membrane (275). PKA phosphorylation of 
PDE4D3 drives an association with the mAKAP signaling complex to evoke rapid signal termination in the 
muscle compartment (276), which may have therapeutic implications given that polymorphisms in the 
PDE4D3-mAKAP binding site lead to a higher susceptibility to cardiovascular disease (277).  PDE4D enzymes 
also get phosphorylated by both casein kinase 1 (CK1) and glycogen synthase kinase 3β (GSK3β) in the 
catalytic region on a motif known as a “phosphodegron” (278). This action increases the affinity of the PDE for 
a ubiquitin ligase complex (Cullin 1 containing SCF E3 ligase) which promotes proteosomal degradation of the 
enzyme (278). Hence PDE phosphorylation not only affects activity, localization, and protein-protein 
interactions, it also regulates protein turnover. 
 It has been known for some time that increases in PKA activity promote the proteosomal degradation 
of short-lived proteins, an action that can be enhanced by PDE inhibitors (c.f., (279)). However, we are just 
starting to understand that the stability of PDEs can themselves be influenced by the ubiquitin-proteosome 
system (Figure 5). Ubiquitin conjugation is known to target proteins for degradation by the proteasome and 
28 
 
specificity is introduced at the level of E3 ligase-substrate interaction. We now know of multiple instances 
where PDEs interact definitively with one of the over 600 E3 ligase types to dramatically shorten PDE half-life 
and this could be a new point at which to direct innovative therapeutics. As mentioned above, PDE4Ds can be 
degraded by virtue of an SCF E3 (278), whereas PDE4B levels can be down-regulated by a different E3, 
Smurf2, to promote anti-fibrotic signaling in the liver (280). PDE4D5 can also be targeted for ubiquitin 
modification by the RING type MDM2 E3 ligase; however, this beta-adrenergic driven ubiquitination of 
PDE4D does not signal a degradation of the enzyme. Instead, it shifts PDE4 from binding RACK1 to binding β-
arrestin (281). PDE4s are similarly regulated by the ubiquitin-like protein SUMO (small ubiquitin-like 
modifier) (5). SUMO-conjugation tends to alter the location, activity or protein-protein interactions of a protein 
rather than tagging for destruction via the ubiquitin-proteosome system (282). Unlike ubiquitination, sites of 
SUMOylation can be predicted in the amino acid sequence of putative substrates as conjugation usually occurs 
on a lysine residue within the consensus h-K-X-D/E (where h is a bulky hydrophobic and X is any residue) 
(282). PDE4s from subfamilies A and D contain the consensus motif, whereas subfamilies B and C do not. This 
adds an extra layer of sub-family-specific regulation as SUMOylation serves both to protect against the 
inhibitory phosphorylation by ERK MAPkinases (283) and further enhances activity of the PKA 
phosphorylated longform PDE4 by locking it in the “open” non-UCR inhibited conformation (5). 
Two additional PTMs that trigger PDEs for destruction include S-nitrosylation and proline 
hydroxylation (Figure 5). PDE5 can be S-nitrosylated by NO on Cys220 (284), which targets the enzyme to the 
proteasome and reduces PDE activity. Under conditions of reduced NO bioavailability, as in heart disease, 
PDE5 is upregulated due to a loss of this S-nitrosylation-induced degradation (284).  Proline hydroxylation has 
also been identified as a modification that can tag substrates for recognition by E3 ligase complexes (285). In 
the heart, proline hydroxylases domain-containing proteins (PHDs) hydroxylate surface-associated prolines on 
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PDE4D enzymes, triggering their degradation (286). In this way, direct binding of PHDs to PDE4s increase 
cAMP without affecting adenylate cyclase activity. 
 
Challenges 
Although this is clearly an exciting time in the PDE field, there is much work that remains to be done. For 
therapeutics to be efficiently developed, we need to have a more thorough understanding of exactly where 
cyclic nucleotide signaling is disrupted in a given disease—in which tissue, cell types, and subcellular 
compartments. We then need to target a PDE in a defined locale, with the understanding that subcellular 
compartmentalization of a given PDE may vary depending on species, age, tissue type, or disease status (10-
19).  This consideration is equally important in the evaluation of potential efficacy and potential side effects. To 
maximize potential efficacy while minimizing potential side effects, one would target a PDE that is enriched, if 
not exclusively expressed, in the tissue of interest and that controls the same pool of cyclic nucleotides that is 
altered by the disease. At the same time, efforts to unravel the intramolecular signals responsible for 
trafficking each PDE also need to continue to inform more sophisticated therapeutic approaches that can 
preferentially target a given PDE in a given subcellular compartment. Along these same lines, we need to grow 
our understanding of how to stimulate PDE activity and how to target the PDE catalytic activity of dual-
specificity PDEs in a functionally-selective manner (i.e., target only its cAMP- or cGMP-hydrolytic activity, see 
(216) for further discussion). Perhaps by increasing the specificity of our approach, we can retain efficacy while 
mitigating the numerous side effects described above that have plagued PDE inhibitors to date. 
 An additional challenge is gain a better understanding of which physiological/disease processes are 
governed by PDE regulation of canonical versus non-canonical cyclic nucleotides. Research into the role of 
non-canonical cyclic nucleotides is rapidly evolving as new techniques and reagents facilitate functional 
studies (9). Cyclic cytidine monophosphate (cCMP) and cyclic uridine monophosphate (cUMP) are 
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synthesized by soluble guanylate and soluble adenylate cyclases in mammalian systems, although an as-yet-
to-be identified generator likely accounts for the majority of production given the dissociation between 
sGC/sAC and cCMP/cUMP expression patterns (9). ExoY, a bacterial nucleotidyl cyclase, is known to generate 
cUMP in non-mammalian systems  (7).  Hydrolysis of cCMP is catalyzed by PDE7A whereas cUMP is broken 
down by  PDE3A, PDE3B and PDE9A (7). Functionally both nucleotides have been shown to activate 
PKA/PKG (287), cyclic nucleotide gated channels (288), and cCMP is described as a partial agonist of EPAC 
(289). In a disease context, the non-canonical cyclic nucleotides play roles in promoting virulence of 
Pseudomonas aeruginosa infections (290) and triggering apoptosis of cancer cells (291); however much more 
research is needed to accurately characterize the pathophysiology involving these signaling molecules. 
Difficult issues facing the field will be defining specific non-canonical cyclic nucleotide signaling systems that 
are aberrantly regulated in disease, determining the mechanisms by which PDEs might preferentially degrade 
non-canonical vs. canonical cyclic nucleotides, and visualising the compartmentalisation of non-canonical 
signalosomes in specific locations within cells and tissues.  
 Finally, development of PDE-targeted therapeutics faces the same challenges as does all drug 
discovery—namely the high rate of failure in clinical trials. A recent study suggests that from 2000-2015, only 
13.8% of all compounds made it from Phase I to approval (292). When considering success rates for individual 
indications, we may gain insight into the likelihood that a PDE-targeted therapeutic will achieve success 
within a given disease area. For example, oncology saw only 3.4% of compounds made it from Phase 1 to 
approval; whereas, metabolic/endocrinology, cardiovascular, CNS, autoimmune/inflammation, genitourinary, 
and opthamology saw a success rate of 19.6%, 25.5%, 15%, 15.1%, 21.6%, and 32.6%, respectively (292). This 
certainly paints a grim picture for pursuing any type of therapeutic in the context of cancer; however, this 
failure rate also underscores the desperate need to develop novel therapeutic options.  It is then important to 
note that success rates were doubled for cancer compounds when patient selection biomarkers were employed 
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in the trials; the success rate for cardiovascular compounds similarly benefited (292). Importantly, expression 
or activity of PDEs themselves may prove viable biomarkers in this context (Box 2). 
 
Outlook 
Although the challenge of targeting localized pools of PDEs for purposes of correcting pockets of aberrant 
cyclic nucleotide signaling has proven difficult in the past, there are indications that innovative approaches 
and technological advances are making headway (see Table 4 for recent patent activity that includes PDE 
activators, biomarkers, and viral approaches). For example, agents that show remarkable selectivity for sub-
families of PDE4 are showing promising results in mouse models of learning and memory and translation to 
human disease would be a game changing advance (135). Additionally, novel delivery systems are being 
developed that can transport PDE inhibitors to precise tissues or cell types, thereby abrogating complications 
associated with systemic distribution (e.g., (293, 294)). In the future, novel delivery systems such as these could 
be employed to deliver agents that specifically disrupt the anchoring of single isoforms. Another approach 
with potential is the intelligent design of a new generation of PDE inhibitors that preferentially accumulate in 
or segregate from certain tissues or organs. The mild side-effect profile of Apremilast is largely due to its 
inability to penetrate the brain and engineering of similar restricted distribution profiles may unlock the latent 
abilities of other PDE inhibitors. Gene therapy that seeks to abrogate or enhance activity of single PDE 
isoforms in a cell type-specific manner may provide a way to combat disease or fight complications associated 
with ageing. There is also the possibility that an improved therapeutic window might be achieved by 
combining sub-optimal doses of PDEi’s with ineffective doses of downstream-target activators, which would 
result in an effective combined dose only in tissues and subcellular compartments where both molecules were 
present (e.g., (295)). Indeed, PKA, PKG, and Epacs have been implicated as therapeutic targets in their own 
right for a number of indications for which PDEi’s are being pursued, including diseases of the cardiovascular, 
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immune, and nervous systems as well as cancer (e.g., (129, 130, 296-300)). Further, several studies in a variety 
of tissues have attributed the beneficial effects of PDEi’s to the activation of PKA, PKG and/or Epac (e.g., (135, 
301-303)).  As we learn more about the functional role and molecular interactions of each PDE splice variant, 
and how the function and/or localization of an individual variant may be altered in a given disease, it will 
become clearer how we can successfully target PDEs in a specific fashion to achieve efficacy while avoiding 
side effects. Only with this detailed level of knowledge will we be able to realize the full potential of PDEs as 





Box 1. Physiological roles of PDEs. 
Because PDEs are ubiquitously distributed and are the only enzymes to degrade 3’,5’-cyclic nucleotides, this 
superfamily of enzymes plays a role in numerous biological processes in health and disease. That said, the 
biological roles played by a given PDE isoform are unique due to its unique expression pattern at the level of 
tissue/organ, cell-type and subcellular compartment (Table S1). 
Most PDEs families are expressed in the nervous system where they regulate neurodevelopment and 
apoptosis, neuronal excitability, synaptic transmission and neuroplasticity (83, 109). Every brain region 
expresses more than one PDE, but no two PDEs exhibit the exact same regional distribution (83). For instance, 
PDE11A is the only PDE with brain expression restricted to the hippocampus. While PDE11A regulates how 
well an individual responds to the mood stabilizer lithium, it does not regulate basal anxiety- and depression-
related behaviors (187). In contrast, PDE4D is expressed in most brain regions and does appear to regulate 
basal depression-related behaviors (e.g., (304)). PDE1B, PDE2A, PDE7B, PDE8B and PDE10A are enriched in 
the striatum relative to other brain regions (83), and each has been implicated in regulating basic motor 
function; whereas, PDE5A and PDE9A have not (for review, see (83, 305)). In the retina, PDE6 function is 
central in mediating activation of the light response in rod and cones photoreceptors, and PDE6 mutations 
cause photoreceptor degeneration in retinitis pigmentosa (237, 306). 
In the cardiovascular system, PDE2, PDE3 and PDE4 isoforms control different subcellular pools of 
cyclic nucleotides to regulate important cardiac functions from myocardial contraction/relaxation to chronic 
cell growth and survival, and disruption of this PDE signaling has been associated with disease (for review, 
see (1)). For example, heart failure has been associated with reduced levels of PDE3A and PDE4D, which 
results in myocyte apoptosis and cardiac arrhythmias, respectively (235, 249). 
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Many cancers have been associated with reduced levels of cAMP and/or cGMP secondary to an 
elevation in PDE activity. For example, chronic lymphocytic leukemia cells exhibit increased PDE7B 
expression; leukemia, colon cancer, and glioma cells overexpress one or more isoforms of PDE4; and colon 
cancer cells and adenocarcinmoas exhibit elevated PDE5 activity (23, 307, 308).  
Inflammation of numerous tissue types can be increased by a drop in cAMP levels that is caused by an 
increase in cAMP-PDE activity.  For example, activity of PDE4—the predominant cAMP-hydrolyzing enzyme 
in the immune system—is elevated in the context of various inflammatory diseases, including psoriasis, COPD 
and asthma (309, 310). 
PDEs are also implicated in reproductive health. Several isoforms are present in granulosa cells as well 
as oocytes in preovulatory follicles of mammalian ovary regulating the meiotic cell cycle (311). Furthermore, 
many PDEs are expressed in cells of the spermatogenic pathway where they may regulate sperm motility (312, 
313), and PDE5 is expressed in the contractile tissues of the male excurrent tract and accessory where its 
increased activity contributes to erectile dysfunction (e.g., (34)). 
 
Box 2. PDEs as disease biomarkers. 
PDEs are also being explored as both diagnostic and patient-selection biomarkers. This super family of 
enzymes, like other genes, can be genotyped from blood samples to assess risk for specific diseases (e.g., high 
suicide risk, (314); PDE8A, NCT02855918). PDE mRNA and protein expression can be measured ex vivo in an 
isoform-specific manner from biopsied samples (e.g, excised tumors). Further,  imaging compounds can be 
engineered with relative ease to selectively target a given PDE family/sub-family in vivo. Thus, PDEs can be 
explored as biomarkers in diseases where tissue is readily biopsied (e.g,. cancers) and diseases where tissue is 
not (e.g., diseases of the brain).  
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Ex vivo biomarkers. Measurement of PDE4D7 is seen as a valuable biomarker for both pre-
surgical and post-surgical risk stratification to optimize treatment decisions (314, 315) (Table 4). 
Studies in patient samples showed that PDE4D7 expression is initially upregulated with the 
development of primary tumours but then is downregulated when the disease progresses to an 
androgen-independent state (e.g., in castration-resistant tumours) (316, 317), consistent with in vitro 
reports using prostate cancer cells (204). The analysis of PDE4D7 expression in biopsy/surgery 
samples has been applied to develop InformMDx™ (licensed by MDxHealth from Philips), a tissue-
based prognostic prostate cancer biomarker test to stratify patients by risk of disease progression and 
secondary tumors and, thus, inform post-biopsy/post-surgery treatment decisions 
(https://mdxhealth.com/press-release/mdxhealth-launch-agreement-philips-prognostic-prostate-
cancer-biomarker; accessed 12/03/18).  
PDE3A may also represent a useful cancer biomarker as it is greatly expressed in certain cancer cell types 
such as squamous carcinoma cell lines or gastrointestinal stromal tumour (GIST) cells (318, 319). Furthermore, 
cancer cell lines with the highest PDE3A expression proved the most susceptible to the chemotherapeutic 
effects of PDE3i’s (320). Thus, PDE3A expression could qualify as a biomarker for patient selection which 
improves patient care by reducing exposure to ineffective drugs and accelerates clinical development of novel 
therapeutic agents by testing them in targeted populations. 
In vivo biomarkers. Altered cyclic nucleotide signaling has been implicated in a variety of age-
related diseases of the brain (c.f., (248)). PDE10A is widely reported as downregulated in both the 
striatum and cortex of patients with Huntington’s disease, with the extent of PDE10A loss 
corresponding to the genetic burden associated with the disease (41, 80, 321, 322). A loss of PDE10A 
expression has also been observed in the basal ganglia of patients with Parkinson’s disease (323). 
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Importantly, highly-specific PDE10A positron emission tomography (PET) tracers shows that 
PDE10A expression in HD patients continues to decline over years (41). Thus, PET imaging of 
PDE10A could be a useful biomarker for assessing the initial diagnosis and subsequent progression 




Figure 1. 11 families of PDEs degrade cyclic nucleotides. Both of the canonical cyclic nucleotide signaling 
pathways (cAMP and cGMP) are composed of numerous molecules responsible for the synthesis, execution, 
and breakdown of their signals. cAMP is synthesized by transmembrane adenylyl cyclases (ACs) that are 
activated by Gαs and inhibited by Gαi (326) as well as soluble ACs that are activated by bicarbonate and 
calcium (327). cGMP is synthesized by particulate guanylyl cyclases (pGCs) that are activated by natriuretic 
peptides and soluble guanylyl cyclases (sGCs) that are activated by nitric oxide (NO) (328). Both cAMP and 
cGMP activate cyclic nucleotide gated channels and allosterically modulate activity of select PDEs (6). In 
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contrast, only cGMP stimulates protein kinase G (PKG); whereas, cAMP activates protein kinase A (PKA), 
exchange protein activated by cAMP (Epac) and popeye domain-containing proteins (POPDC)(329). Signaling 
through either the cAMP or cGMP pathways ultimately leads to phosphorylation of a myriad of downstream 
targets, including the transcription factor cAMP response element binding protein (CREB). In addition to 
cAMP and cGMP, several PDEs also hydrolyze the non-canonical cyclic nucleotides (not included) cUMP 
(PDE3A, PDE3B, PDE9A), cCMP (PDE7A), and c-di-GMPa (bacterial PDEs), albeit with much lower affinity (7, 
8).  
 
Figure 2. The 21 phosphodiesterase (PDE) genes are grouped into families (name and substrate specificity 
listed to right of each illustration) based on the homology of their C-terminal catalytic domain (represented as 
a semi-ellipse). Due to alternate promoters and splicing events, each PDE family has multiple isoforms that 
differ in terms of the length and complexity of their N-terminal regulatory domains (depicted with different 
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shapes), which are thought to regulate subcellular trafficking, substrate affinity, and catalytic activity. The 
relative size and domain distances were drawn based on estimations from the Pfam/uniprot database, with the 
exception of the REC domain of PDE8 (estimated from (330)) and the second CaM domain of PDE1 (estimated 
from (313)). Illustrations represent the longest isoform for gene A of each PDE family. CaM, calmodulin-
binding domain; GAF, cGMP-binding PDEs Anabaena adenylyl cyclases and E. coli FhlA; TM, transmembrane 





Figure 3. Mechanisms that activate phosphodiesterase (PDE) catalytic activity. A) Calcium-calmodulin 
(CaM) binding to the CaM domains of PDE1 relieves N-terminal auto-inhibition of the catalytic site, thereby 
promoting enzymatic activity (331). B) Cyclic nucleotides binding to GAF domains of dimeric PDEs (shown 
here: cGMP binding the GAF-B domain of PDE2) are thought to promote catalytic activity by inducing an 
outward rotation of the catalytic domains and, thus, enabling access to substrates (332).C) Phosphorylation by 
PKA or PKG activates several PDEs (6). In the case of PDE4D, phosphorylation of the UCR1 domain by PKA 
causes UCR1 to bind its own UCR2 domain instead of the catalytic site of the other monomer, thereby locking 
the enzyme in an active state. D) PDE activity can also be modulated by protein-protein binding interactions. 
One such well-characterized example involves membrane-bound PDE6, where the rhodopsin-activated G-
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protein α-subunit transducin displaces the inhibitory PDE6γ C-termini from the catalytic sites on PDE6αβ, 
thus, promoting cGMP hydrolysis (333). 
Figure 4. Methods for targeting phosphodiesterase signaling with increasing specificity. Given the vast 
diversity of PDE isoforms, each with unique tissue expression profiles, subcellular compartmentalization, and 
protein-protein interactions, it is becoming clear that selective targeting of PDE function will be required to 
achieve efficacy while diminishing undesirable side effects. Small molecule inhibitors (e.g., cilomilast) are 
readily developed with family-specific selectivity (e.g., targeting PDE4 over PDE3); however, isoform 
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specificity remains a challenge (e.g., cilomilast inhibits PDE4D with only 7-fold selectivity versus PDE4B) (334). 
Conversely, gene therapy (i.e., expressing a recombinant construct to knock down or restore expression of a 
given PDE isoform) and dominant negative approaches (i.e., expressing a catalytically inactive PDE4D5 that 
displaces the endogenous isoform from its interacting partners) can target isoform subtypes exclusively (e.g., 
targeting PDE4D5 but not PDE4D3 nor PDE4B). That said, dominant negative approaches would influence 
signalling within all microdomains regulated by that isoform. The greatest specificity can be achieved with 
peptide/small molecule binding disruptors or mutagenesis approaches (not shown) that are designed  to 
prevent a specific PDE isoform from binding a specific partner, thus, altering signaling only within one specific 
complex. As shown here, a disruptor peptide that specifically prevents the interaction between PDE4D5 and β-
arrestin would lead to the recruitment of EPAC1 to β2 adrenergic receptors (βAR), but would leave PDE4D5 







Figure 5. Phosphodiesterase (PDE) regulation by post-translation modification (PTM). Cyclic nucleotide 
dynamics can be modulated by the addition of different functional groups to PDEs. Phosphorylation is a very 
common mechanism to control PDE activity as depicted by the action of PKA on PDE4D3. Both enzymatic 
activity and binding affinity of PDE4D3 for mAKAP are increased by PKA phosphorylation, allowing a faster 
signal termination in myocytes (276). Palmitoylation of PDE10A2 in its N-terminal region translocates the 
enzyme to the plasma membrane, although its phosphorylation by PKA can prevent the action of the 
palmitoyl acyltransferase (zDHHC) (169). Ubiquitination can influence PDEs function through the control of 
their stability. For example, the E3 ubiquitin ligase Smurf2 targets PDE4B for degradation which leads to the 
attenuation of liver fibrosis (280). S-nitrosylation can also tag PDEs for destruction. Thus, the covalent 
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incorporation of nitric oxide (NO) to the GAF-A domain of a PKG-phosphorylated and active PDE5, directs 
the enzyme to the proteasome (284). Hydroxylation of proline residues has emerged as another PTM to 
stimulate turnover of PDEs. Prolyl hydroxylase domain protein 2 (PHD2) action on PDE4D increases its 
recognition by E3 ligase complexes in cardiomyocytes (286). Finally, SUMOylation can intensify the activity of 
PDE4A and PDE4D. The SUMO transfer from the E2 conjugase UBC9-E3 enzyme PIASy complex to the PDEs, 
enhances their activation by PKA phosphorylation and repress their inhibition induced by ERK activity (5). 
  
Table 1. Marketed PDE inhibitors 
Generic name 
(Trade name) 
Indication Approved (year) Side effects 




FDA (1979), Canada (1965), 
approved worldwide 
Nausea, vomiting, diarrhea, 





FDA (1940), Canada (1957), 
several countries 
Stomach pain, diarrhea, headache, 




FDA (1981), Canada (1975), 
Europe 
Stomach pain, nausea, vomiting, 
diarrhea, headache, irritability, 





FDA (1951), Canada (1962), 
Europe, Japan  
Stomach pain, nausea, vomiting, 
diarrhea, headache, irritability, 
restlessness, insomnia flushing, and 
increased urination 
Pentoxifylline Intermittent Claudication 
FDA (1984), Canada (1984), 
approved worldwide 
Belching, bloating, upset stomach, 
nausea, vomiting, indigestion, 
dizziness, and flushing, headache 
PDE1    
Vinpocetine 
Cerebral vascular 
disorders and memory 
impairment  
Europe, Mexico and Asia. 
USA as an over-the-counter 
dietary supplement 




PDE3                 
Cilostazol Intermittent Claudication 
FDA (1998), EMA (2000), 
Japan (1988), Asia and 
South America 
Headache, palpitations, diarrhea, 
dizziness, nasal irritation and 
pharyngitis 
Milrinone Congestive Heart Failure 
FDA (1987), EMA (2016), 
Canada (1995), Japan, China 
Ventricular/supraventricular 
arrhythmias, hypotension and 
headache 
Amrinone  Congestive heart failure 
FDA (1984), Canada (1984), 
China 
Thrombocytopenia, nausea, diarrhea, 
hepatotoxicity, arrhythmias and fever 
Enoximone Congestive heart failure Some countries in Europe 
Headache, diarrhoea, insomnia, 
hypotension, vomiting, nausea, 
tachycardia and arrhythmias 
Olprinone  Heart failure Japan (1996) 
Cardiac dysrhythmias and 
thrombocytopenia 
Pimobendan  Heart failure Japan (1994) 
Headache, palpitation, nausea and 
ventricular arrhythmias 
Anagrelide Thrombocythemia 
FDA (1997), EMA (2004), 
Canada (1998), several 
countries 
Headache, diarrhea, unusual 
weakness/fatigue, hair loss, nausea 
and dizziness 





FDA (2011), EMA (2010), 
Canada (2010), Russian 
Federation, South Korea 
Diarrhea, weight loss, nausea, 
headache, insomnia, decreased 
appetite  
Apremilast 
Psoriasis and psoriatic 
disorders 
FDA (2014), EMA (2014), 
Canada (2014) 




dermatitis (patients >2 
years old) 
FDA (2016), Canada (2018) Hypersensitivity reactions of the skin 
Drotaverine  
Functional bowel 
disorders and alleviating 
pain caused by smooth 
muscle spasm  
Asia and Eastern European 
countries 




PDE3, 10, 11) 
Asthma and dizziness 
related to cerebral 
infarction   
Japan (1989), South Korea 
(2002) Nausea, diarrhea and abdominal pain, 
depression, rash and fatigue 





PDE10, 3, 2A) 
Anxiety 
Japan (1985), several 
European countries 
(Hungary, 1974), Jamaica, 
Thailand and Argentina 
(1982) 
Nausea, stomach discomfort, dry 
mouth, skin rash, insomnia, vomiting 
and drowsiness 
PDE5                           
Sildenafil 
Erectile Dysfunction 
FDA (1998), EMA (1998), 
Canada (1998), approved 
worldwide 
Headache, flushing, dyspepsia, nasal 
congestion, and impaired vision, 
including photophobia and blurred 
vision Pulmonary arterial 
hypertension (PAH) 
FDA (2014), EMA (2005) 
Canada (2006) 
Vardenafil Erectile Dysfunction 
FDA (2003), EMA (2003), 
Canada (2004), several 
countries 





FDA (2003), EMA (2002), 
Canada (2003), approved 
worldwide Headache, dyspepsia, back pain and 
myalgia 
PAH 
FDA (2009), EMA (2008), 
Canada (2010) 
Avanafil Erectile Dysfunction FDA (2012), EMA (2013) 
Headache, flushing, and 
nasopharyngitis 
Udenafil 
Erectile dysfunction and 
hypertension 
South Korea (2005), Russian 
federation (2008), Thailand, 
Colombia, Malaysia and the 
Philippines 
Headache, dizziness, reddening, nasal 
congestion, dyspepsia and impaired 
vision  
Mirodenafil Erectile Dysfunction South Korea (2007) 
Flushing, headache, nasal congestion, 




FDA (1961), Canada (1962), 
several European countries, 
Japan, Taiwan, Russian 
Federation  
Headache, dizziness, nausea, 
diarrhea, muscle pain and vomiting  
PDE10A   
Papaverine 
Visceral spasm and 
vasospasm and erectile 
Dysfunction 
FDA, Canada (1951), 
approved worldwide 
Ventricular tachycardia, diarrhea, 







                  Table 2. Clinical trials involving PDEs inhibitors that failed to reach the market for the described indication 
Compound / 
Manufacturer 




PDE2     
PF-05180999 / Pfizer 
Healthy volunteers 
(schizophrenia) 














Phase I / Withdrawn 
prior to enrollment 
2014 
NCT01981486 
PDE2/5     












Phase II / Completed 
2008 
NCT00039520 
Non-small cell lung 
cancer 






Small cell lung cancer 
Phase II / Completed 
2008 
NCT00041054 
Prostate cancer and 
prostatic neoplasms 








Phase II / Completed 
2011 
NCT00841204 
PDE3     
Cilastozol (Pletal) / 
Otsuka 
Pharmaceuticals 
Type 2 diabetes 
polyneuropathy 






PDE4     
ASP9831 / Astellas Non-alcoholic Phase II / Completed NCT00668070 Lack of 
47 
 
Pharma steatohepatitis (NASH) 2010 (63) efficacy 
PDE5     
Sildenafil (Viagra or 
Revatio) or Tadalafil 
(Cialis or Adcirca) / 




Early Phase I/Phase I 






Sildenafil (Viagra or 
Revatio) / Pfizer 
DMD and Becker 
Muscular Dystrophy 
(BMD) 












Tadalafil (Cialis or 
Adcirca) / Eli Lilly 
BMD 











Vardenafil (Levitra) / 
Bayer/GSK 
Type 2 diabetes 






PDE9     











PF-04447943 / Pfizer AD 






PDE10     
PF-02545920 (a.k.a. 
MP-10) / Pfizer 
 
Schizophrenia 



























































efficacy MP-10 Huntington's Disease 







Phase I / Completed 
2015 
NCT02208934 Change in 
therapeutic 
indication 
(cancer) Huntington's Disease 
Phase I / Terminated 
early 2016 
NCT02907294 
Reported on Clinicaltrials.gov (accessed 04/30/19). Information is included for all clinical trials involving 





       Table 3. Selected clinical trials involving PDEis pursued for new indications  
Compound / 
Manufacturer 
Indication Phase / Status Clinical trial ID 
PDE3, 4, 10, 11    
Ibudilast (AV-411, MN-
166) / MediciNova 
Opioid withdrawal 






Phase I / Completed 
2013 
NCT01217970 (91, 92) 
Alcohol use disorder 
Phase I / Completed 
2015 
NCT02025998 (94) 




Phase II / Completed 
2017 
NCT01740414 (93, 337) 
Amyotrophic lateral 
sclerosis (ALS) (Biomarker 
study) 
Phase II / Active, not 
recruiting 
NCT02714036 
PDE1    
ITI-214 / Intracellular 
Therapies 
Schizophrenia  
Phase I / Terminated 
early 2014  
NCT01900522  
Parkinson's Disease  
Phase I/II / Completed 
2018 
NCT03257046  
Healthy volunteers (CNS 
engagement) 
Phase I / Recruiting NCT03489772  
 Systolic heart failure Phase I/II / Recruiting NCT03387215  









Not Applicable / 
Completed 2017 
NCT02857829 
PDE2    
TAK-915 / Takeda 
 Healthy volunteers (PET 
imaging, schizophrenia) 
Phase I / Completed 
2016 
NCT02584569  
Healthy volunteers  
Phase I / Completed 
2016 
NCT02461160 
PDE3    
Cilostazol (Pletal) / 
Otsuka 
Pharmaceuticals 
Type 2 diabetic 
atherosclerosis 
Phase IV / Completed 
2010-2012 
NCT01252056, 
NCT00823849 (339)  
Chronic tinnitus  
Not applicable / 
Completed 2013 
NCT01378650 (108) 
 Alzheimer's Disease 
Phase IV / Completed 
2013 
NCT01409564 (340) 
Atherosclerotic events in 
type 2 diabetes 
Phase IV / Unknown NCT00886574 
 Mild Cognitive Impairment 
Not applicable / 
Completed 2015 
NCT01872858 
Ischemic events in type 2 
diabetic artery obstruction 
Phase IV / Recruiting  NCT02983214 
Antiplatelet aggregation in 
type 2 diabetes 
Phase IV / Active, not 
recruiting 
NCT03248401  
Antiplatelet aggregation in Phase IV / Recruiting NCT02983214 
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type 2 diabetes 
Antiplatelet aggregation in 
type 2 diabetes 
Phase IV / Unknown NCT02933788 
PDE4    
Apremilast (Otezla) / 
Celgene Corp. 
Vitiligo 




Lichen Planus of Vulva 




BPN14770 / Tetra 
Discovery 
Alzheimer's Disease 





Phase II / Not yet 
recruiting 
NCT03817684  
Fragile X Syndrome (FXS) Phase II / Recruiting NCT03569631 
Crisaborole (Eucrisa) / 
Pfizer 








Roflumilast (Daxas or 
Daliresp) / Astrazeneca 
Polycystic Ovary Syndrome  
Phase IV / Completed 
2014 
NCT02037672, 
NCT02187250 (122, 123) 
Cognitive deficits in 
schizophrenia  
Phase II / Completed 
2015 
NCT02079844 (126) 
Cognition (Dementia)  




(125, 127, 341) 
Insulin and Blood Sugar 
Levels in Prediabetic 
Overweight and Obese 
Individuals  
Phase I/II / Completed 
2017 
NCT01862029 (342) 









Syndrome (PET imaging) 
Phase I/II / Recruiting NCT02743377 
TAK-648 / Takeda Type 2 diabetes 





Zembrin / ND Aged Individuals 
Phase I / Completed 
2012 
NCT01805518 (52) 






Not Applicable / 
Unknown 
NCT01564303 
ND Diabetic nephropathy 
Not Applicable / 
Unknown 
NCT01566006 
Sildenafil (Viagra or 
Revatio) / Pfizer 
Diabetic cardiomyopathy 
(type 2 diabetes) 




(Skeletal muscle insulin 
signaling) 
Phase IV / Completed 
2016 
NCT02129725 
 Urolithiasis/urinary stones 
Phase IV / Active, not 
recruiting 
NCT02519153 
Migraine aura  Early Phase I / Recruiting  NCT02795351 
Solid tumors  
Phase I / Active, not 
recruiting 
NCT02466802 (165) 




6007) / Strategic 
science and 
technologies/Dare 
Sexual arousal disorder 
Phase II / Completed 
2017 
NCT02570282 
Tadalafil (Cialis or 
Adcirca) / Eli Lilly 
Type 2 Diabetes 
(Postprandial 
Hyperglycemia) 
Phase I / Terminated 
early 2011  
NCT01238224 
Head and neck squamous 
cell carcinoma 
Phase II / Completed 
2012-2016 
NCT00894413 (167)  
Head and neck squamous 
cell carcinoma 








sensitivity in obesity  
Phase IV / Completed 
2015 
NCT02595684 (343) 
Aortic stenosis (AS) left 
ventricular 
remodeling/hypertrophy 
Phase IV / Terminated 
early 2017 
NCT01275339 
Multiple myeloma (MM) 
Phase II / Terminated 
early 2017  
NCT01374217 
Insulin Resistance in Type 2 
Diabetes  
Phase II / Recruiting  NCT02601989 
Diabetic cardiomyopathy 
(DC) 
Phase IV / Recruiting  NCT01803828 
Endocrine cardiomyopathy Phase II / Recruiting  NCT02611258 (344) 
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in Cushing Syndrome (CS) 
Access sheath deployment 
(Nephrolithiasis/kidney 
stones) 
Phase IV / Enrolling 2019  NCT03229889 
Lower urinary tract 
symptoms (prostatic 
hyperplasia) 




Phase II / Recruiting NCT02819440 
Anti-tumor Mucin 1 
vaccine efficacy in head 
and neck squamous cell 
carcinoma (HNSCC) 
Phase I/II / Recruiting NCT02544880 
Small Vessel Disease 
Phase II / Active, not 
recruiting 
NCT02450253 (345) 
PDE9    
PF-04447943 / Pfizer Stable sickle cell disease  
Phase I / Completed 
2016 
NCT02114203 (346) 
BI 409306 / Boehringer 
Ingelheim 
Healthy volunteers 


















Phase I / Completed 
2013-2016 
NCT01892384, 




Phase II / Recruiting 
NCT03351244, 
NCT03230097 
Drug-drug interactions  











 Huntington's Disease (PET 
imaging) 








Cancer Phase I / Recruiting NCT03786484 
EVP-6308 (now FRM-



















TAK-063 / Takeda 
Schizophrenia 










Reported on Clinicaltrials.gov (accessed 04/30/19) with an end date after April 2009 









Table 4. Selected recent patents involving PDEs 







PDE4 inhibitor and purpose for 
preparing novel anti-
inflammatory drugs 
Hu Y Hu Y 12/08/2018 30/11/2018 
WO201816714
2 
Treatment of idiopathic 
pulmonary fibrosis [with a 
PDE4 inhibitor] 
Takeda GMBH 
Hanauer G,  





Immunodetection method for 
various PDE5 inhibitor drugs 
Univ South China 
Agricult 
Shen Y, Hua Y, 
Xu Z, Yang J, 
Wang H, Sun 
Y, Lei H 
18/04/2017 15/09/2017 
CN107412214
A Application of PDE4 Inhibitor 
Guangzhou 
Lanssonpharm 
Xu L 31/07/2017 01/12/2017 
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[FCPR16 for the treatment of 
PD] 
Jianzhi Tech Co 
Ltd 
US2019046528 
Method of preventing hair loss 
or promoting hair growth by 
using PDE3 inhibitor 
Seoul Nat Univ 
Hospital 
Kwon O,  Choi 





Rhodopsin PDE [as an 
optogenetic tool for light control 









Application of PDE4 inhibitor 
ZL-N-91 in preparation of 
medications for lung cancer 





Zhao AZ,  
Gong S,  Lin Y,  
Li F,  Li X 
05/02/2016 27/12/2018 
CN107287239 
Gene therapy vector and 




Biological Tech Co 
Ltd 
Pang J 11/04/2016 24/10/2017 
CN107312824 
Applications of PDE3A in 
determination of tumor 




Yu Q,  Liu J 26/04/2016 03/11/2017 
CA2975049 
PDE inhibitors to repair brain 
and/or retinal injury in human 
newborns 
Wintermark P Wintermark P 10/08/2016 10/02/2018 
AU2017317575 
Treatment of nonalcoholic fatty 
liver disease [with PDE4 
inhibitors] 
Takeda GMBH 
Hanauer G,  




T cells with increased 
immunosuppression resistance 
[expressing PDEs for the 
treatment of cancer] 
Adaptimmune Ltd 





Compounds and their use as 
PDE4 activators [for the 
treatment of disorders requiring 
a reduction of cAMP] 
Mironid Ltd 




PDE4 inhibitor for the treatment 
of diabetic nephropathy 
Takeda GMBH 
Hanauer G,  
Vollert S,  




Method of treating insomnia 
[with PDE5 inhibitors] 





PDE9 inhibitor and levodopa 










Treatment of multiple sclerosis 
with combination of 
Laquinimod and a PDE4 
inhibitor 
Teva Pharma,  
Piryatinsky V,  
Kaye J 




Treatment of cognitive 
impairment with combination 
therapy [of a PDE4 inhibitor 
and an Acetylcholinesterase 
inhibitor] 
Univ Maastricht 
Yamada T,  
Prickaerts J,  
Van Duinen M,  




Composition comprising PDE5 
inhibitor for inhibiting apoptosis 
of nerve cells 
Aribio Inc,  Sk 
Chemicals Co Ltd 
Kim MH,  




Novel composition for the 
treatment of cystic fibrosis [with 
a PDE4 inhibitor and a 
prostacyclin] 
Scipharm Sarl 
Freissmuth M,  
Gloeckel C,  




PDE inhibitors for transvaginal 
use in the treatment of infertility 







Treatment of addiction and 
impulse-control disorders using 
PDE7 inhibitors 
Omeros Corp 












RNAi-mediated inhibition of 
PDE4 for treatment of cAMP-




Yanni JM,  
Chatterton JE,  




Use of PDE3 inhibitors for the 
reduction of heart size in 





Daemmgen J,  
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